• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share

    Investing News Network
    Oct. 31, 2016 09:23AM PST
    Biotech Investing

    Simulations Plus, Inc. (NASDAQ: SLP) announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders.

    Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation
    and modeling software for pharmaceutical discovery and development,
    today announced that its board of directors has declared its next
    ongoing quarterly cash dividend of $0.05 per share to its shareholders.
    This cash dividend will be distributed on Thursday, November 17, 2016,
    to shareholders of record as of Thursday, November 10, 2016.
    Walt Woltosz, chairman and chief executive officer of Simulations Plus,
    said: “This dividend declaration is a continuation of the Board’s plan
    to distribute a cash dividend of $0.05 per share per quarter. Of course,
    the board always has the discretion of discontinuing, increasing, or
    decreasing the dividend in accordance with the cash needs of the
    business.”
    About Simulations Plus, Inc.

    Simulations Plus, Inc., is a premier developer of groundbreaking drug
    discovery and development software, which is licensed to and used in the
    conduct of drug research by major pharmaceutical and biotechnology
    companies worldwide. The company is a global leader focused on improving
    the ways scientists use knowledge and data to predict the properties and
    outcomes of pharmaceutical and biotechnology agents. Our innovations in
    integrating new and existing science in medicinal chemistry,
    computational chemistry, pharmaceutical science, biology, and physiology
    into our software have made us the leading software provider for
    physiologically based pharmacokinetic modeling and simulation as well as
    a leading provider of both preclinical and clinical pharmacometric
    consulting services for regulatory submissions. For more information,
    visit our website at www.simulations-plus.com.

    biotechnology companiesboard of directors
    The Conversation (0)

    Go Deeper

    AI Powered
    Life Science Outlook

    Life Science Outlook

    BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

    BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
      • Electric Vehicles
    • Agriculture
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Energy
      • Uranium
      • Oil and Gas
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Robotics
      • Crypto
      • Cleantech
    Life Science
      • Biotech
      • Cannabis
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES